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ORIGINAL ARTICLE
Whole-body computed tomography versus conventional
skeletal survey in patients with multiple myeloma: a study
of the International Myeloma Working Group
J Hillengass1,2, LA Moulopoulos3, S Delorme2, V Koutoulidis3, J Mosebach2, T Hielscher4, M Drake5, SV Rajkumar6, B Oestergaard7,
N Abildgaard7, M Hinge7, T Plesner8, Y Suehara9, K Matsue9, N Withofs10, J Caers11, A Waage12, H Goldschmidt1, MA Dimopoulos13,
S Lentzsch14, B Durie15 and E Terpos13
For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However,
recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis
compares sensitivity and prognostic signiﬁcance of WBCT and CSS in patients with smoldering MM (SMM) and MM. Fifty-four of 212
patients (25.5%) had a negative CSS and a positive WBCT for osteolytic lesions (Po0.0001). Of 66 patients with SMM based on CSS,
12 (22.2%) had osteolytic lesions on WBCT. In comparison, WBCT failed to detect some bone destructions in the appendicular
skeleton possibly due to limitations of the ﬁeld of view. Presence of lytic bone lesions in WBCT was of borderline prognostic
signiﬁcance (P= 0.051) for SMM patients, with a median time to progression of 38 versus 82 months for those without bone
destructions. In conclusion, WBCT identiﬁes signiﬁcantly more sites of bone destruction than CSS. More than 20% of patients with
SMM according to CSS have in fact active MM detectable with WBCT. On the basis of this and other studies, WBCT (either computed
tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for
the detection of osteolytic lesions in MM.
Blood Cancer Journal (2017) 7, e599; doi:10.1038/bcj.2017.78; published online 25 August 2017
INTRODUCTION
For decades, conventional skeletal survey (CSS) has been the
standard imaging technique for the detection of myeloma bone
disease.1,2 It consists of conventional X-rays of multiple skeletal
sites (skull, spine, pelvis, chest, femora and humeri). CSS was the
basis for the Durie/Salmon staging system and for the guidelines
of the International Myeloma Working Group (IMWG) as of 2003.3,4
Earlier publications had shown, however, that the sensitivity of
conventional X-rays for bone damage assessment was limited, as
changes were not detected until at least 30–50% of bone mass
was destroyed.5 Computed tomography (CT), with its ability to
provide three-dimensional information of the examined region is
as expected more sensitive than projection X-ray studies. Since
bone is a high-contrast organ (mineralized bone versus fat-
containing bone marrow), CT radiation doses needed for optimal
skeletal imaging are lower than those required for differentiating
soft tissue pathologies. Therefore, dedicated low-dose, whole-
body CT protocols have been developed for skeletal imaging.
Several studies have already investigated the use of whole-body
CT (WBCT) in patients with monoclonal plasma cell disorders,
showing that WBCT is more sensitive for detecting skeletal lesions
than plain X-ray ﬁlms.6–9 Therefore, more modern cross-sectional
imaging techniques have been implemented into the updated
guidelines of the IMWG for the diagnosis of multiple myeloma
(MM).10 However, concerns have been raised that due to the
higher sensitivity of WBCT, bone changes might be detected
earlier but might not yet be clinically relevant. In this setting,
patients would be classiﬁed as having symptomatic myeloma but
would not beneﬁt from earlier initiation of treatment.
This study aimed to both, compare the sensitivities of WBCT and
CSS for the detection of skeletal lesions, and to determine whether
additional lesions detected by WBCT are of prognostic relevance.
Given logistical challenges in identifying patients who have been
examined with both CSS and WBCT almost simultaneously,
previous studies comparing both techniques have mostly
included comparatively few patients. Further, studies investigating
the prognostic signiﬁcance of earlier detection of myeloma bone
disease is lacking. To address these deﬁciencies, the IMWG
decided to perform a retrospective, international multicenter
analysis of patients with smoldering multiple myeloma (SMM) who
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had, for any reason, been examined with both conventional X-ray
and WBCT within 30 days.
PATIENTS AND METHODS
Inclusion criteria for patients in the current analysis were histologically
proven MM with WBCT and CSS obtained within 30 days. Furthermore,
the mentioned questionnaire had to contain all of the required
clinical information to allow for disease staging. For the comparison of
CSS and WBCT pretreated patients were also included; for the analysis
of the prognostic signiﬁcance of imaging ﬁndings only untreated
patients.
Data acquisition
For the current retrospective analysis, we collected data, CSS and WBCT
studies from a total of 283 patients from eight different centers worldwide.
From this cohort, 212 patients with myeloma (66 with smoldering
myeloma) fulﬁlled the inclusion criteria. Of this 212 patients, 159 were
untreated at time point of imaging. A list of contributing centers can be
found in the Supplementary Data (Supplementary Table 1). Compact discs
with pseudonymized imaging data of WBCT and CSS were sent to the
organizing center and uploaded to a dedicated workstation running a local
installation of Osirix MD (Pixmeo SARL, Bernex, Switzerland), a commer-
cially, FDA-approved picture archiving and communication system (PACS)
that provides all tools for viewing and analyzing radiological images,
equipped with a monitor certiﬁed for medical use. Furthermore,
questionnaires were completed by each of the centers collecting clinical
data of the patients.
Image analysis was performed in consensus reading by three
experienced radiologists (LAM, SD, VK) blinded to the clinical data of the
patients. WBCT and CSS studies were read several months apart, so that
the readers were unable to attribute WBCT and CSS images of one patient
to each other. Lesions were classiﬁed as ‘deﬁnitely present’, ‘probably
present’, ‘probably absent’ and ‘deﬁnitely absent’ for each lesion and in the
following locations: Skull, cervical spine, thoracic spine, lumbar spine, sacral
bone, iliac bones, sciatic bones, pubic bone, sternum, left rib cage (Ribs L),
right rib cage (Ribs R), left scapula, right scapula, left clavicle, right clavicle,
left humerus, right humerus, left femur and right femur, respectively.
Furthermore, the presence of hyperdensities, either focal or diffuse, in the
medullary cavity of the femora or humeri was recorded but was not
analyzed for the present comparative study.
Patient characteristics available data
Median age of the patient group was 66.1 years (age range 40.2–91.9
years). Median time interval between WBCT and CSS was 1 day − 29 to
30 days. Patient characteristics are shown in Table 1.
Deﬁnitions and limitations of collected data
Some osseous locations were not included in CSS in some centers. In such
cases, only those osseous locations having valid measurements for both
WBCT and CSS methods were considered.
SMM and MM were deﬁned according to the current guidelines of the
IMWG.10 Bone disease-deﬁning CRAB criteria were based on lytic lesions
results from CSS.
Statistical analysis
For statistical tests, ‘deﬁnitely present’ and ‘probably present’ entries were
merged and counted as lytic lesions. WBCT and CSS were tested for
difference in detection sensitivity with the exact McNemar test including
odds ratio and 95% conﬁdence interval. The 95% conﬁdence interval for
difference in paired proportion was calculated. Time to progression (TTP)
of disease was calculated from time of CSS onwards. Log-rank test was
used to compare TTP between groups. Aalen–Johansen estimator was
used to estimate the cumulative incidence of progression accounting for
death as competing event. Analysis was performed with statistical software
R 3.3.0 (Vienna, Austria).
RESULTS
Comparison of different techniques in the entire patient cohort
A total of 212 patients were included in the analysis for
comparison of the WBCT and CSS imaging techniques. In 103
patients (48.6%), no lytic bone lesions were detected with either
technique, and in 43 patients (20.3%) lesions were detected with
both CSS and WBCT. In 12 patients (5.7%), lytic lesions were seen
in CSS but not by WBCT. In 54 patients (25.5%), lytic bone lesions
were seen by WBCT but not on CSS (odds ratio 4.50 (2.38–9.24);
Po0.0001).
Table 2 shows the numbers of patients with deﬁnitely or
probably positive, as well as probably or deﬁnitely negative results
in CSS and WBCT, respectively.
Detection differences of CSS and WBCT for lytic bone lesions
based on anatomic location
The difference in detection sensitivity for WBCT and CSS was
dependent on the location of the lesions in the skeleton. WBCT
Table 1. Patient characteristics
Parameter N %
Stage at time point of imaging
MM 146 68.8
SMM 66 31.0
Serum heavy chain
IgA 48 23 Jan
IgD 1 0.5
IgG 131 63.0
IgG + IgA 1 0.5
IgM 1 0.5
None 26 12 May
Light chain
Kappa 120 58.0
Lambda 82 39.4
Not determined 5 2 Apr
ISS at diagnosis
Stage 1 89 47.6
Stage 2 69 36.9
Stage 3 29 15 May
Abbreviations: Ig, immunoglobulin; ISS, International Staging System; MM,
multiple myeloma; SMM, smoldering multiple myeloma.
Table 2. Lytic bone lesions in CSS and WBCT, respectively, for the
whole patient group
CSS WBCT
Deﬁnitely
present
Probably
present
Probably
absent
Deﬁnitely
absent
Total
Deﬁnitely present 34 2 0 5 41
16.0% 0.9% 0% 2.4% 19.3%
Probably present 7 0 1 6 14
3.3% 0% 0.5% 2.8% 6.6%
Probably absent 11 4 2 10 27
5.2% 1.9% 0.9% 4.7% 12.7%
Deﬁnitely absent 33 6 8 83 130
15.6% 2.8% 3.8% 39.2% 61.3%
Total 85 12 11 104 212
40.1% 5.7% 5.2% 49.1% 100.0%
Abbreviations: CSS, conventional skeletal survey; WBCT, whole-body
computed tomography.
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was overall superior, particularly in the axial skeleton. CSS
detected slightly more bone destruction only in the humeri, a
fact which in some cases may be attributable to limitations in the
ﬁeld of view with WBCT (Figure 1). Of the 12 patients in whom
WBCT was negative but there was suspicion of lytic lesions in CSS,
in only 5 patients were lesions deﬁned as ‘deﬁnitely present’. In six
remaining patients, osteolytic lesions were determined to be
‘probably present’, while in one patient, lesions in CT were
counted as ‘probably absent’ and as ‘probably present’ in CSS. In
total, these were 21 lytic lesions, of which 11 were localized to the
long bones (clavicle, femur, humerus, ribs), and 10 in the axial
skeleton (skull, spine, pelvis). Detection rates depending on
location in the skeleton are shown in Figure 2 and
Supplementary Table 2.
SMM patients
After review of the clinical data provided by the contributing
centers and the results of CSS, 66 patients were identiﬁed as
having SMM according to the 2003 IMWG guidelines, with 54 of
the 66 being untreated. Those 54 patients were included in the
current analysis.
In 42 of the untreated SMM patients (77.8%), both CSS and
WBCT techniques did not show any lesions. In 12 patients,
however, WBCT identiﬁed osteolytic lesions (22.2%), while CSS was
by deﬁnition negative (P= 0.0005) (Table 3).
Sensitivity of WBCT was most signiﬁcantly superior to CSS in the
spine and pelvis as shown in Figure 3. Those patients in whom CSS
showed bone destructions in the appendicular skeleton (partly
missed by WBCT) did, by deﬁnition, not fulﬁll the criteria of SMM
and were not included in this analysis.
In comparing clinical parameters in patients with SMM, we
found the patients who had bone destruction present when
assessed by WBCT had signiﬁcantly higher serum creatinine values
(P= 0.03), but were, by deﬁnition, not beyond the limit necessary
for the initiation of anti-myeloma treatment. No other signiﬁcant
differences between the groups were identiﬁable (for clinical
questionnaire see Supplementary Appendix).
Osteoporosis, as deﬁned by standard radiological criteria, was
detected by both techniques in 14 SMM patients. In 12 patients,
osteoporosis was detected by WBCT only, and in 12 patients,
osteoporosis was detected only on CSS (odds ratio 12.0; P= 0.003).
In four patients, WBCT showed osteoporosis with fracture. In these
patients, CSS showed neither osteoporosis nor a fracture.
Prognostic signiﬁcance of WBCT ﬁndings in patients with SMM
The 12 SMM patients who had lytic bone lesions on WBCT had a
higher probability of progression to symptomatic myeloma than
those with no lytic bone lesions in WBCT (log-rank P= 0.05)
(Figure 4). However, no prognostic signiﬁcance for overall survival
was identiﬁable. None of the SMM patients progressed within the
ﬁrst 2 months after imaging. SMM patients with lytic bone lesions
Figure 1. X-rays (left) and CT (right) showing the limited ﬁeld of view for some CT protocols in which the arms had been placed above the
head. In such cases, the elbows protruded outwards, and as a result, the distal humeri were either ‘cut off ’ or lay in the ﬁeld periphery where
the image quality of many CT scanners is limited.
Figure 2. Detection differences (including 95% conﬁdence intervals)
between WBCT and X− ray for the whole patient group in %. CS,
cervical spine; LS, lumbar spine; TS, thoracic spine.
Table 3. Lytic bone lesions identiﬁed by CSS and WBCT, respectively,
for SMM patients
CSS WBCT
Deﬁnitely
present
Probably
present
Probably
absent
Deﬁnitely
absent
Total
Probably absent 1 1 2 5 9
(1.9%) (1.9%) (3.7%) (9.3%) (16.7%)
Deﬁnitely absent 10 0 2 33 45
(18.5%) 0% (3.7%) (61.1%) (83.3%)
Total 11 1 4 38 54
(20.4%) (1.9%) (7.4%) (70.4%) (100.0%)
Abbreviations: CSS, conventional skeletal survey; SMM, smoldering multi-
ple myeloma; WBCT, whole-body computed tomography.
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J Hillengass et al
3
Blood Cancer Journal
identiﬁed by WBCT had a median TTP of 38 months compared to
82 months in patients without lytic bone lesions, and a 2-year
progression-free survival of 58% versus 33%, respectively.
Osteoporosis was not of prognostic signiﬁcance. However, if a
patient with SMM had an osteoporotic fracture, his/her risk for
progression was be increased (hazard ratio (HR) 2.03; conﬁdence
interval 0.57–7.24), although not signiﬁcantly, possibly due to the
small number of patients.
Prognostic signiﬁcance of WBCT ﬁndings in patients with MM
In the 79 untreated MM patients, 48 (60.8%) showed osteolyses in
CT while in 40 (50.6%) patients osteolyses were found in CSS. A
difference between both imaging techniques was found with CT
positivity and CSS negativity in 16 (20.3%) and CSS positivity with
CT negativity in 8 (10.1%) of MM patients, respectively. No
prognostic signiﬁcance was found for the presence of lytic bone
lesions identiﬁed by either technique (progression-free survival:
P= 0.3 and OS: P= 0.4).
DISCUSSION
Due to the expected higher sensitivity of CT over CSS, several
centers worldwide have already switched from CSS to WBCT for
examining myeloma bone disease, using either CT alone or as part
of a positron emission tomography (PET)-CT protocol. The latest
guidelines of the IMWG also recommend initiating therapy if CT
imaging shows one or more lytic bone lesions.10 However,
concern has been raised that detection of bone lesions earlier
might trigger systemic treatment at a time when it is not yet
necessary, thus causing unnecessary potential treatment side
effects or complications to patients.
Therefore, this study sought to determine how frequently bone
lesions are detected by WBCT in patients who, per former criteria,
would not have needed treatment, and to learn whether patients
with positive WBCT but negative CSS are at increased risk for
earlier MM progression. Since, owing to radiation dose concerns,
WBCT and CSS are rarely performed at the same time, eight
centers within the IMWG agreed to retrospectively collect imaging
and clinical data from patients in whom WBCT and CSS had been
performed for any reason (for example, CSS and PET-CT, CT as new
standard and CSS as part of a clinical trial and so on) within
30 days. Another beneﬁt of performing this analysis was that
different imaging protocols would be available for comparison,
which would aid in establishing minimal requirements for WBCT
protocols. Guidelines on this topic will be published separately by
the participating radiologists.
The current multicenter study investigating 212 evaluable
patients conﬁrms that in 20–25% of patients with negative CSS,
WBCT will detect destructive bone lesions. This is compatible with
earlier but smaller studies, which revealed that conventional CT
imaging is superior to imaging by plain X-ray in 51, 32, 18 and 35
patients with MM, respectively.7,9,11,12 Horger et al.13 were the ﬁrst
to perform a feasibility study comparing a WBCT protocol to CSS in
100 patients with Monoclonal Gammopathy of Undetermined
Signiﬁcance and partly pretreated patients with MM, which
showed that CT provided an adequate detection rate of lytic
bone lesions and was useful to determine fracture risk. In that
study, however, no plain ﬁlm X-rays were available for comparison.
Kröpil et al. compared ﬁndings of WBCT and CSS in 29 partially
pretreated patients with MM in Durie and Salmon stages I–III. In 18
patients, 97 lesions were detected exclusively by WBCT.8 Further,
in a heterogeneous cohort of 52 patients with monoclonal plasma
cell disorders, Wolf et al.6 found more lytic bone lesions by WBCT
compared to CSS in 12 patients (23%), a similar rate to that
determined in our study. Finally, a recent study from Mayo Clinic
investigated 188 patients with SMM with PET-CT. In 122 evaluable
patients, 16 (13%) showed PET positivity and lytic bone lesions in
the CT portion of the PET-CT.14 False negative results of WBCT
occurred particularly in the upper extremities, and scans that were
performed for attenuation correction in PET-CT and/or with the
arms were placed above the head. In the former case, the tube
current is very low, that is, even lower than in a dedicated skeletal
low-dose CT. The reason is that the diagnostician focusses mainly
on reading the PET study and uses the CT scans solely for the
attenuation correction of the PET raw data, and to attribute an
Fluorodeoxyglucose-avid focus to an anatomical location. In the
latter case, positioning the arms above the head, with the elbows
pointing outside, the distal humeri, elbows and proximal forearms
will typically lie outside the ﬁeld for which the CT scan is
reconstructed. The result will be that the X-rays are attenuated not
only by the objects within the reconstructed ﬁeld of view but also
by structures outside of it. This causes malcalculations during the
image reconstructions and to a signiﬁcant degradation of the
image quality particularly in the periphery of the ﬁeld of view.
Typically, the density values will be too high, and there will be
additional streak artefacts and also increased image noise.
Figure 3. Detection differences (including 95% conﬁdence intervals)
between WBCT and CSS in patients with SMM in %.
Figure 4. Cumulative incidence of progression to symptomatic MM
in patients with or without osteolytic lesions by WBCT.
Computed tomography versus X-ray in myeloma
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Since generalized osteoporosis is difﬁcult to detect by standard
plain ﬁlms and is also subject to a variety of inﬂuences including
aging, osteoporosis per se is no longer a criterion for myeloma
bone disease in the current IMWG guidelines.10 In our cohort,
WBCT was signiﬁcantly superior to CSS for detecting osteoporosis,
particularly for the identiﬁcation of osteoporotic fractures, as in
four patients, osteoporotic fractures were invisible by CSS. Thus
although clinically relevant, a radiological diagnosis of osteoporo-
sis in the absence of lytic bone lesion should be used carefully
when making clinical care decisions in patients with monoclonal
plasma cell disorders.
Analysis of different sites within the skeleton revealed that CT
was signiﬁcantly superior at detecting osteolytic lesions in the
axial skeleton. With some CT protocols, however, the distal
portions of the humeri lay outside the ﬁeld of view, so that lesions
in these regions would be missed. This was particularly evident in
studies in which the arms had been placed above the head with
the elbows bent, as is commonly the case in examinations of the
body trunk. We therefore recommend that, in WBCT protocols
performed for plasma cell disorders, the arms be placed alongside
the body and that the scans include both the skull up to the vertex
as well as the entire femora and knees. Since beam hardening
artefacts may arise if the arms are permitted to lie on the couch at
the same level as the spine, thereby degrading the image quality
of the vertebrae, it is likely preferable to instruct patients to fold
their hands in front of the body, which places the arms in an
elevated position and not at the same level as the vertebrae. Since
with modern multislice CT scanners a WBCT scan lasts less than a
minute, such a position is easy to maintain for vast majority of
patients.
In the mentioned study from Mayo Clinic, SMM patients with
PET-positive lytic bone lesions had a TTP to symptomatic disease
of 21 months, as compared to 60 months for patients without lytic
lesions.14 In the current analysis, bone destruction detected by
WBCT imaging alone was likewise of prognostic signiﬁcance, with
a median TTP of 83 months in patients without versus 38 months
in patients with lytic lesions, and a 2-year progression-free survival
probability of 58% versus 33%, respectively. It cannot be entirely
excluded that the presence of lytic bone lesions in WBCT could
have led to an earlier initiation of treatment in some cases. We are
unable to trace which events led to the diagnosis of symptomatic
MM in individual cases, and have no information on whether the
lytic bone lesions that had escaped detection in the CSS were
actually seen in the WBCT. Since, however, the shortest TTP was
longer than 2 months, we consider it unlikely that the diagnosis of
symptomatic MM was immediately elicited by the results of the
WBCT study.
The current ﬁndings do not answer the question of which
imaging technique should be used under which conditions. While
magnetic resonance imaging (MRI) has the highest sensitivity for
the detection of diffuse bone marrow plasma cell inﬁltration, PET-
CT and MRI are similarly sensitive for detecting focal lesions,15,16
and WBCT (alone or done as part of PET-CT) is the best technique
for detecting damage to mineralized bone.17 In one study, both
PET-CT and MRI were shown to predict progression if they were
still positive after therapy, with PET-CT being superior to MRI.18–20
For most clinical purposes, the CT part of a PET-CT scan can
replace a separate WBCT. Nevertheless, it must be noted that this
would require that the tube current to be of sufﬁcient intensity.
Often, the CT portion of PET-CT only serves for attenuation
correction and is obtained with very-low-tube currents—far below
that needed for true low-dose skeletal CT protocols. Although the
skeleton is a high-contrast organ, they are hard to assess on such
images, due to excessive image noise—and so was the case in
some CT scans that were read in this study. Furthermore, some
device should be used to support the arms and place them at an
elevated level above the couch, since patients will not be able to
maintain such position during an entire PET scan. The only
signiﬁcant difference between SMM patients with solely osteo-
lyses in CT compared to others was a higher creatinine in serum
reﬂecting presumably a more advanced stage of disease.
Since the current study was focused on comparing WBCT and
CSS strictly for the detection of bone lesions, incidental ﬁndings
were not a target of this study. However, Surov et al.21 were able to
show 295 incidental ﬁndings in 93 MM patients, 22% of which were
determined to be clinically signiﬁcant. WBCT imaging is of limited
value in the detection of bone marrow inﬁltration without frank
osteolysis, especially in the cancellous bone of the spine and pelvis,
because CT density at those sites is a function of both the bone
marrow composition and the presence of mineralized bone
trabeculae, making it difﬁcult to determine whether the fatty bone
marrow component has been replaced by a cellular myeloma
inﬁltrate. In this setting, MRI would be the imaging technique of
choice. In the long bones of adults, however, fatty conversion of the
hematopoietic marrow has taken place, which makes it easy to
detect abnormal cellular inﬁltrates, either diffuse or nodular. Nishida
et al.22 have shown that inﬁltration of the appendicular skeleton by
MM not only increased from Monoclonal Gammopathy of
Undetermined Signiﬁcance to SMM to MM, but that it is also of
borderline prognostic signiﬁcance for MM patients. Finally, although
we recorded the presence of hyperdense inﬁltrations of the
medullary cavities of the proximal long bones, analysis of these
ﬁndings was not performed in the current comparative study.
In addition to being more sensitive in detecting clinical
important osteolytic bone lesions compared to CSS, WBCT is also
faster and more convenient for patients. However, there are some
drawbacks: ﬁrst the radiation dose even of modern low-dose CT
protocols is ~ 2–4 times higher than that of at least digital CSS.
Furthermore, CT is only able to display bone marrow inﬁltration
outside the long bones because soft tissue signal is overlain by the
trabecular bone in the vertebrae and the pelvis. Therefore, in this
case PET and MRI have to be utilized to examine inﬁltration of
malignant cells on regions where no bone destruction has
occurred yet.23,24
CT imaging has already been included in the new IMWG guidelines
for the diagnosis of MM.25 The current study lends support to the
revisions made in the revised IMWG diagnostic criteria for myeloma.
Our study includes the largest number, so far, of SMM and MM
patients in a comparative analysis of WBCT and CSS, conﬁrmed not
only that WBCT is signiﬁcantly more sensitive than CSS for detecting
myeloma-related osteolyses, but also that lytic bone lesions detected
by WBCT alone are indeed prognostically signiﬁcant for the
progression of SMM into MM. It remains to be determined under
which conditions whole-body MRI would be preferred over WBCT, a
question which is beyond the scope of this study.25 In some
circumstances MRI imaging may be needed in addition to WBCT,
such as patients with SMM to detect focal lesions. In summary, we
recommend the use of WBCT (alone or as part of a PET-CT protocol)
instead of CSS for the evaluation of patients with suspected
myeloma, and in the follow-up of patients with SMM and MM.26
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